Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2) is a research paper published in Rheumatology and Therapy (2020). On theSindex it has a DataRank of 0.907. It has been cited 18 times, with 16 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.442
From this paper's citation signal
Citation Network Contribution
0.465
From 14 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 16 citers.
NIAMS NIH HHS
Grant: P30 AR070254
Eli Lilly and Company
FWCI
1.26
Citation Percentile
0.8%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals